• Tandem Diabetes Care recently expanded its t:slim X2 insulin pump with Control-IQ+ automated insulin delivery to work with Abbott’s FreeStyle Libre 3 Plus continuous glucose sensor in five European countries, giving users 15-day wear and minute-by-minute data across both the pump and mobile app.
• This move broadens CGM choice for Tandem’s existing pump base and could strengthen its ecosystem appeal as it pursues wider European adoption.
• We’ll now explore how this added Libre 3 Plus compatibility might influence Tandem’s investment narrative, particularly around international expansion and ecosystem strength.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Tandem Diabetes Care Investment Narrative Recap

To own Tandem Diabetes Care, you need to believe in broader pump adoption, recurring high-margin supplies, and a stickier AID ecosystem. The Libre 3 Plus integration in Europe directly supports the international expansion catalyst by widening CGM choice, but it does little to reduce near term execution risk in commercial retooling and the shift toward pharmacy and direct channels, where operational complexity and competitive pressure remain central concerns.

The recent CE mark for expanded Control IQ+ indications in Europe, including use in type 1 pregnancy and adults with type 2 diabetes, sits alongside Libre 3 Plus compatibility as part of a broader effort to serve more patient segments internationally. Together, these updates reinforce the international growth catalyst around direct sales and ecosystem strength, while still leaving open questions about how quickly they can offset flat renewals and rising competition in Tandem’s core markets.

Yet, against these positives, investors should be aware of how intensifying competition could...

Tandem Diabetes Care's narrative projects $1.4 billion revenue and $63.4 million earnings by 2029. This requires 10.3% yearly revenue growth and a $157.9 million earnings increase from -$94.5 million today.

Uncover how Tandem Diabetes Care's forecasts yield a $29.20 fair value, a 93% upside to its current price.

Exploring Other Perspectives

While consensus focuses on steady international growth, the most optimistic analysts see Libre 3 Plus integration amplifying already bold forecasts of about US$1.6 billion revenue and US$170.9 million earnings by 2029, highlighting how much views can differ and why it is worth comparing several scenarios before deciding what you believe.

Explore 3 other fair value estimates on Tandem Diabetes Care - why the stock might be worth over 4x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Tandem Diabetes Care research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Tandem Diabetes Care research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tandem Diabetes Care's overall financial health at a glance.

No Opportunity In Tandem Diabetes Care?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.